Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.

Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G Ann Hematol. 2014 Feb,93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N. Mod Pathol. 2014 Jun,27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA Lancet Oncol. 2014 Jan,15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, et al. Ann Oncol. 2014 Feb,25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.

Gampenrieder SP, Romeder F, MuГџ C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R. Anticancer Res. 2014 Jan,34(1):227-33.

Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays – implications for response-guided therapy in genotype 1 infections.

Taylor N, Haschke-Becher E, Greil R, Strasser M, Oberkofler H. Antivir Ther. 2014,19(5):449-54. doi: 10.3851/IMP2723. Epub 2014 Jan 16.

UPDATED REPORT OF THE AUSTRIAN CML REGISTRY

Schmidt, S, Sill, H, Greil, R, Burgstaller, S, Schlogl, E, Petzer, A HAEMATOLOGICA. 2014, 99: 341-341.

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM Blood. 2014 Apr 3,123(14):2157-60. doi: 10.1182/blood-2013-11-536557. Epub 2014 Jan 23.

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, et al. Clin Cancer Res. 2014 Mar 1,20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.

Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, Greil R. Leuk Res. 2014 Apr,38(4):475-83. doi: 10.1016/j.leukres.2014.01.006. Epub 2014 Jan 18.